CP-25,a compound derived from paeoniflorin:research advance on its pharmacological actions and mechanisms in the treatment of inflammation and immune diseases  

作　　者：Xue-zhi Yang Wei Wei 

机构地区：[1]Institute of Clinical Pharmacology,Anhui Medical University,Key Laboratory of Anti-inflammatory and Immune Medicine(Anhui Medical University),Ministry of Education,Antiinflammatory Immune Drugs Collaborative Innovation Center,Hefei 230032,China

出　　处：《Acta Pharmacologica Sinica》2020年第11期1387-1394,共8页中国药理学报（英文版）

基　　金：supported by the National Natural Science Foundation of China(Nos.81673444,81330081 and 81973332).

摘　　要：Total glycoside of pae ony(TGP)has been widely used to treat in flammation and immune diseases in China.Pae on i florin(Pae)is the major active comp orient of TGP.Although TGP has few adverse drug reactio ns,the slow onset and low bioavailability of Pae limit its clin ical use.Enhan ced efficacy without in creased toxicity is pursued in developi ng new age nts for in flammatio n and immu ne diseases.As a result,paeoniflorin-6z-0-benzene sulfonate(CP-25)derived from Pae,is developed in our group,and exhibits superior bioavailability and efficacy than Pae.Here we describe the development process and research advance on CP-25.The pharmacokinetic parameters of CP-25 and Pae were compared in vivo and in vitro.CP-25 was also compared with the first-line drugs methotrexate,leflunomide,and hydroxychloroquine in their efficacy and adverse effects in arthritis animal models and experimental Sjogren's syndrome.We summarize the regulatory effects of CP-25 on inflammation and immune-related cells,elucidate the possible mechanisms,and analyze the therapeutic prospects of CP-25 in inflammation and immune diseases,as well as the diseases related to its potential target G-protein-coupled receptor kinases 2(GRK2).This review suggests that CP-25 is a promising agent in the treatment of inflammation and immune diseases,which requires extensive investigation in the future.Meanwhile,this review provides new ideas about the development of anti-inflammatory immune drugs.

关 键 词：paeoniflori n-6'-0-be nzene sulfo nate(CP-25) total glycoside of paeo ny PAEONIFLORIN in flammation and immu ne diseases G-protein-coupled receptor kinases 2(GRK2) 

分 类 号：R96[医药卫生—药理学]